Drugs / BIA 3-202
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT02779348 | Sep → Dec 2006 | — | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02772614 | Jan → Feb 2006 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02774564 | Sep → Nov 2005 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02778594 | Sep → Nov 2005 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02763839 | Apr → Jul 2001 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02763852 | Apr → Jul 2001 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02763800 | Sep 2000 → Jan 2001 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02763787 | Apr → Jun 2000 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02834507 | Mar → Nov 2005 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIA 3-202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02763787 ↗ |
| Route | Oral | “BIA 3-202 was administered in the form of oral tablets” NCT02763787 ↗ |